Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine

@article{Conway2001DevelopmentOD,
  title={Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine},
  author={Brian Conway and Mark A. Wainberg and David B. Hall and Marianne Harris and Peter Reiss and David A. Cooper and Stefano Vella and R. Curry and Patrick A. Robinson and Joep M. A. Lange and J S G Montaner},
  journal={AIDS},
  year={2001},
  volume={15},
  pages={1269-1274}
}
ObjectiveTo evaluate the development of phenotypic and genotypic resistance to zidovudine, didanosine and nevirapine as a function of the virologic response to therapy in a group of drug-naive individuals receiving various combinations of these agents. DesignAll patients were enrolled in a double-blind controlled randomized trial (the INCAS study) and were selected for detailed resistance studies based on specimen availability and virologic response. MethodsWithin the three study groups… Expand
Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China
TLDR
The drug resistance strains were highly prevalent in antiretroviral-treated patients, and increased with the continuation of therapy, with many patients encountering virological failure after 6 months therapy. Expand
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
TLDR
The emergence of NVP resistance must be weighed against the simplicity, efficacy, and cost effectiveness of SD-NVP prophylaxis in PMTCT settings in developing countries. Expand
Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
TLDR
Nevirapine extended release will further increase the durability and persistence of nevirapine-containing antiretroviral therapy, allowing once-daily dosing regimens. Expand
Predictive Factors and Selection of Thymidine Analogue Mutations by Nucleoside Reverse Transcriptase Inhibitors According to Initial Regimen Received
TLDR
There was no statistical difference in the number of mutations between the two groups of patients, however, thymidine analogue mutations were more frequent in patients who added didanosine to zidovudine monotherapy compared with those who added zalcitabine. Expand
Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing
TLDR
The hypothesis the drug-resistant HIV-1 may be less pathogenic than wild-type virus is supported, and that continued use of HAART might provide clinical benefit, despite persistent viremia and HIV- 1 drug resistance is supported. Expand
New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data
TLDR
Once-daily dosing options are essential to treatment simplification strategies, which have been shown to enhance regimen compliance and durabiltiy, and are especially important due to the low genetic barrier to resistance generally associated with NNRTIs. Expand
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort
TLDR
The findings strongly support the use of 3TC+d4T and3TC+AZT as the nucleoside analogue combination in NVP-based antiretroviral therapy and the presence of hepatotoxicity was associated with HCV-Ab positive patients. Expand
Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia
TLDR
The prevalence of major drug resistance mutations among ARV-treated patients with detectable VL is high in Kuala Lumpur, Malaysia, and genotypic drug resistance testing is important for monitoring patients experiencing ARV regimen failure. Expand
Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview
TLDR
NNRTI and boosted PI regimens provide the highest rates of VS in treatment-naive HIV-infected persons and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects. Expand
Antiretroviral (ARV) drug resistance in the developing world.
TLDR
Evidence provided by longitudinal analyses suggests that, among women taking intrapartum single dose nevirapine (SD-NVP) to prevent mother-to-child transmission of HIV, both the overall prevalence of NNRTI resistance as well as the frequency of mutant virus in the overall viral population decreases with time since SD-N VP prophylaxis was received. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 17 REFERENCES
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial
TLDR
Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied, suggesting that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance. Expand
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay
TLDR
The susceptibility to DDI tends to mildly decrease with drug exposure; the susceptibility to AZT improves with time off AZT; baseline susceptibilities to D DI have a wide range, and the CD4 response may correlate with the initial susceptibility; and a PBL-based microtiter assay is useful for screening clinical isolated for dideoxynucleoside susceptibility profiles. Expand
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
TLDR
In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year. Expand
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
TLDR
Drug susceptibility and mutations in the reverse transcriptase (RT) gene were analyzed with virus isolates from 38 patients treated with nevirapine, a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) RT, documenting that the circulating virus population can change rapidly, and many alternative mutants can emerge, often in complex mixtures. Expand
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
TLDR
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound. Expand
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
TLDR
Analysis of major and minor isolates obtained from both patients soon after onset of the recipient's primary HIV infection illness confirmed that an HIV-1 variant mutant at codons 70, 98, and 181 of the viral reverse transcriptase was transmitted. Expand
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
TLDR
Failure of potent protease inhibitor therapy to suppress HIV RNA levels below detectable levels is common in clinical practice, and can often be explained by their suboptimal use. Expand
Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy
TLDR
The results demonstrate that suppression of pVL below 20 copies/ml is necessary to achieve a long-term antiretroviral response and support the need for a revision of current therapeutic guidelines for the management of HIV infection. Expand
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
TLDR
Accumulating data from clinical and pathogenesis studies continue to support early institution of potent antiretroviral therapy in patients with HIV infection, and increased complexity in HIV management requires ongoing monitoring of new data for optimal treatment of HIV infection. Expand
A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs
TLDR
A new method for high-throughput analysis of clinical samples that permits the simultaneous detection of HIV type 1 (HIV-1) phenotypic resistance to both RT and PR inhibitors by means of recombinant virus assay technology is described. Expand
...
1
2
...